



11 September 2019

To whom it may concern

In the European Union, two quadrivalent meningococcal vaccines protecting against serogroups A, C, Y and W135 has been licensed for use by the European Medicines Agency (EMA).

Menveo[®] was first licensed in March 2010 and renewed in December 2014. In children ≥ 2 years and in adults, one dose is recommended.

Nimenrix[®] was first licensed in April 2012 and renewed in February 2017.

In children between 6 weeks of age and up to 6 months, the first vaccine may be given as from 6 weeks of age and the second dose must be given a minimum of 2 months later. A third (booster) dose is recommended at 12 months of age.

In children from 6 months and up to 12 months of age: a single dose of Nimenrix[®] may be given and the second dose is recommended at 12 months of age, with a minimum interval of 2 months.

In children ≥ 1 year and in adults one dose is recommended.

In Denmark, Statens Serum Institut (SSI) is responsible for purchase and distribution of vaccines to the population. Normally, SSI holds both the above described licensed products in stock.

Due to a national short-out, Menveo[®] is presently not available why individuals with a need for protection against meningococcal disease will be vaccinated with Nimenrix[®] which is considered equally protective in adults.

The short-out on Menveo[®] is expected to last until mid November 2019.

Best regards,

Peter Henrik Andersen
Senior Medical Officer
Department of Infectious Disease Epidemiology and Prevention
Artillerivej 5
DK-2300 Copenhagen S
Denmark
Ph. +45 3268 3265
Email: pea@ssi.dk